← Back to patent-cliff list
TAS-119
Tier C — Watch / tradeTAS-119
Taiho Pharmaceutical Co., Ltd.
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AURKA
Indications (approved)：Leukaemia, Myeloproliferative neoplasm, Myelodysplastic syndrome, Lymphoma, Graft-versus-host disease, Breast cancer, Solid tumour, Non-small cell lung cancer
Regional status
US
Phase II
2022-03-17
EU
Discontinued
2014-09-01
China
Phase I
2021-12-21
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TAS-119?
Approved indications include: Leukaemia, Myeloproliferative neoplasm, Myelodysplastic syndrome, Lymphoma, Graft-versus-host disease, Breast cancer, Solid tumour, Non-small cell lung cancer.
When does the TAS-119 patent expire?
No public expiry year is available for TAS-119 yet; this page updates once verified.
How do I get a quote for TAS-119 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05